Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Michigan study tests ways to boost genetic testing in cancer patients

NCT ID NCT05162846

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to see if these approaches made it more likely for people to complete testing within six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

793 people

The number who actually took part.

Started

Apr 2022

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to speak and read English * Access to the internet * Completed the Family Health History Tool (FHHT) * Meeting clinical criteria for genetic evaluation due to any of the below: 1. Personal history of Breast cancer either: * i. Diagnosed under 50 * ii. Personal or family history of triple negative breast cancer * iii. Ashkenazi Jewish ancestry * iv. Male proband * v. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer 2. Personal history of prostate cancer either: * i. Diagnosed under 50 * ii. Ashkenazi Jewish ancestry * iii. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer 3. Personal history of any cancer or no personal history of cancer with either: * i. PREMM score ≥ 2.5% * ii. 1st degree relative with pancreatic, or male breast cancer * iii. 1st or 2nd degree relative with ovarian cancer * iv. 1st degree relative with any of these cancers diagnosed under 50: colon, endometrial, or breast * v. Ashkenazi Jewish ancestry and 1st or 2nd degree relative with breast cancer 4. Personal history of endometrial cancer diagnosed under 50 5. Personal history of colorectal cancer diagnosed under 50 6. Personal history of renal cancer diagnosed under 46 7. Personal history of sarcoma diagnosed under 46 and a 1st or 2nd degree relative with sarcoma, breast cancer, or brain cancer diagnosed under 56 8. Personal history of brain cancer diagnosed under 46 and a 1st or 2nd degree relative with sarcoma, breast cancer, or brain cancer diagnosed under 56 9. Personal history of any two of the following cancers with at least one of them diagnosed under 46: breast, sarcoma, or brain 10. Personal history of ovarian cancer 11. Personal history of pancreatic cancer 12. Personal history of adrenal cortical carcinoma Exclusion Criteria: * Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal cortical carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.